Illumina Board Changes, Nominates David King
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Should l Buy ILMN?
Illumina announced changes to its Board of Directors. Frances Arnold, PhD, Robert Epstein, MD, and Gary Guthart, PhD, will retire from the Board in connection with the company's upcoming annual meeting of shareholders, and the Board has nominated David King to be elected as a member of the Board. King is the former Executive Chairman and CEO of Laboratory Corporation of America Holdings, and currently serves as a director and chair of both Privia Health and AmSurg Corporation, and as a director of Smith & Nephew.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ILMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to fall
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 143.240
Low
40.50
Averages
133.54
High
170.00
Current: 143.240
Low
40.50
Averages
133.54
High
170.00
About ILMN
Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Rating Updates
- Nvidia Price Target Raised: UBS raised Nvidia's price target from $245 to $275, anticipating first-quarter revenue around $81 billion, suggesting a $3 billion beat against market expectations, highlighting the company's robust growth potential in the AI sector.
- Amazon Alexa Shopping Advantage: Bank of America reiterated its buy rating on Amazon, stating that the new Alexa for Shopping will replace Rufus, leveraging personalized recommendations to enhance user experience and further solidify Amazon's leadership in the e-commerce market.
- Apple Stock Price Target Increase: Evercore raised Apple's price target from $330 to $365, projecting that even with modest iPhone unit growth, the company can achieve low to mid-teens EPS and free cash flow growth due to durable services growth and ASP tailwinds from premium models.
- Starbucks Price Target Upgraded: TD Cowen raised Starbucks' price target from $106 to $120, citing multiple tangible drivers for positive sales revisions in a strong market backdrop, and forecasting margin recovery as labor investments are prioritized.
See More
Trump's Business Delegation for Summit with China
- Delegation Composition: Trump's business delegation for the summit includes over a dozen CEOs from companies like Tesla, BlackRock, and Illumina, aiming to address long-standing business issues with China, highlighting U.S. firms' commitment to the Chinese market.
- Tangible Demands: Companies participating in the summit are required to present a 'tangible ask' to secure concrete outcomes during or after the meeting, reflecting the urgency and expectations of U.S. businesses regarding U.S.-China relations.
- Regulatory Approval Challenges: Meta faces a directive from China's state planner to unwind its $2 billion acquisition of an AI startup, illustrating the increasing regulatory pressures on U.S. tech investments in China, with firms hoping the summit will yield policy support to navigate these challenges.
- Payment Market Opportunities: Mastercard and Visa aim to leverage the summit to enhance their positions in China's payment market, with Mastercard already approved for yuan transaction clearing, while Visa seeks 100% ownership of a future joint venture, indicating strong aspirations for market entry.
See More
Markets Hit New Highs as Tech Stocks Surge
- Tech Stocks Surge: Stocks like Lumentum, Coherent, Corning, Western Digital, Micron, Seagate, Qualcomm, and Qnity Electronics have all risen over 5%, indicating strong market confidence in the tech sector, which may drive overall market gains further.
- Energy Stocks Rise: Energy stocks increased alongside oil prices after President Trump indicated challenges to the Iran ceasefire, reflecting market sensitivity to energy price fluctuations that could impact consumer spending and overall economic growth.
- Consumer Confidence Dips: Consumer-related stocks, including TJX Companies and Nike, faced declines, highlighting investor anxiety over the potential economic pressures from rising energy prices, which could dampen consumer spending.
- CPI Report Expectations: The upcoming Consumer Price Index report is expected to show a significant month-over-month increase, with economists predicting a 0.59% rise from March, which may prompt government actions to alleviate economic burdens on consumers, further influencing market sentiment.
See More
Trump Invites Top Executives for China Trip
- Executive Delegation: President-elect Trump has invited top executives, including Tesla's Elon Musk and Apple's Tim Cook, to join his trip to China, aiming to enhance U.S.-China business cooperation through high-level engagement.
- Broad Agenda: The summit is expected to cover a wide range of topics, including trade, artificial intelligence, export controls, Taiwan, and the Iran war, indicating a desire to ease tensions through dialogue after recent escalations.
- Business Deal Expectations: Trump hopes to secure a series of business deals and purchase agreements during the visit, which, if successful, could enhance U.S. companies' competitiveness in the Chinese market and foster bilateral economic relations.
- Diverse Executive List: The delegation includes executives from various sectors, such as Stephen Schwarzman of Blackstone and Jane Fraser of Citigroup, reflecting U.S. companies' commitment to the Chinese market and willingness to collaborate.
See More
Illumina Reports Q1 Results Exceeding Revenue Expectations
- Performance Exceeds Expectations: Illumina's Q1 revenue reached $1.09 billion, reflecting a 4.8% year-on-year growth that surpassed analyst expectations of $1.07 billion, indicating strong performance in the genomics sector and potential for stock price appreciation.
- Profitability Improvement: The adjusted EPS was $1.15, exceeding the $1.05 consensus estimate by 9%, while adjusted operating income stood at $239 million with a 21.9% margin, showcasing the company's success in cost control and operational efficiency.
- Strong Clinical Demand: Clinical sequencing now accounts for over 65% of the company's consumables revenue, with more than 80 NovaSeq X instruments placed in the quarter, driving revenue growth and indicating sustained demand for high-throughput sequencing.
- Innovation-Driven Growth: Illumina plans to launch new high-throughput flow cells and spatial transcriptomics solutions to enhance the capabilities of the NovaSeq X platform, expected to further expand market share and strengthen competitive positioning.
See More
Illumina Q1 2026 Earnings Call Highlights
- Performance Exceeds Expectations: Illumina reported Q1 revenue of $1.09 billion, exceeding the midpoint of guidance by $20 million, primarily driven by strong instrument and clinical consumable sales, indicating sustained growth potential in clinical markets.
- Guidance Raised for the Year: Management raised the 2026 revenue outlook to $4.52 billion to $4.62 billion and non-GAAP EPS expectations to $5.15 to $5.30, reflecting confidence in future performance and robust market demand.
- Product Innovation Progress: Illumina launched TruPath and is on track to introduce its spatial transcriptomics offering later this year, showcasing the company's ongoing commitment to technological innovation aimed at solidifying its market leadership.
- Expanded Buyback Program: The company repurchased 2 million shares for approximately $242 million in Q1 and announced an additional $1.5 billion share repurchase program, demonstrating management's confidence in future growth and commitment to shareholders.
See More
Latest Wall Street Rating Updates
- Nvidia Price Target Raised: UBS raised Nvidia's price target from $245 to $275, anticipating first-quarter revenue around $81 billion, suggesting a $3 billion beat against market expectations, highlighting the company's robust growth potential in the AI sector.
- Amazon Alexa Shopping Advantage: Bank of America reiterated its buy rating on Amazon, stating that the new Alexa for Shopping will replace Rufus, leveraging personalized recommendations to enhance user experience and further solidify Amazon's leadership in the e-commerce market.
- Apple Stock Price Target Increase: Evercore raised Apple's price target from $330 to $365, projecting that even with modest iPhone unit growth, the company can achieve low to mid-teens EPS and free cash flow growth due to durable services growth and ASP tailwinds from premium models.
- Starbucks Price Target Upgraded: TD Cowen raised Starbucks' price target from $106 to $120, citing multiple tangible drivers for positive sales revisions in a strong market backdrop, and forecasting margin recovery as labor investments are prioritized.
See More
Trump's Business Delegation for Summit with China
- Delegation Composition: Trump's business delegation for the summit includes over a dozen CEOs from companies like Tesla, BlackRock, and Illumina, aiming to address long-standing business issues with China, highlighting U.S. firms' commitment to the Chinese market.
- Tangible Demands: Companies participating in the summit are required to present a 'tangible ask' to secure concrete outcomes during or after the meeting, reflecting the urgency and expectations of U.S. businesses regarding U.S.-China relations.
- Regulatory Approval Challenges: Meta faces a directive from China's state planner to unwind its $2 billion acquisition of an AI startup, illustrating the increasing regulatory pressures on U.S. tech investments in China, with firms hoping the summit will yield policy support to navigate these challenges.
- Payment Market Opportunities: Mastercard and Visa aim to leverage the summit to enhance their positions in China's payment market, with Mastercard already approved for yuan transaction clearing, while Visa seeks 100% ownership of a future joint venture, indicating strong aspirations for market entry.
See More
Markets Hit New Highs as Tech Stocks Surge
- Tech Stocks Surge: Stocks like Lumentum, Coherent, Corning, Western Digital, Micron, Seagate, Qualcomm, and Qnity Electronics have all risen over 5%, indicating strong market confidence in the tech sector, which may drive overall market gains further.
- Energy Stocks Rise: Energy stocks increased alongside oil prices after President Trump indicated challenges to the Iran ceasefire, reflecting market sensitivity to energy price fluctuations that could impact consumer spending and overall economic growth.
- Consumer Confidence Dips: Consumer-related stocks, including TJX Companies and Nike, faced declines, highlighting investor anxiety over the potential economic pressures from rising energy prices, which could dampen consumer spending.
- CPI Report Expectations: The upcoming Consumer Price Index report is expected to show a significant month-over-month increase, with economists predicting a 0.59% rise from March, which may prompt government actions to alleviate economic burdens on consumers, further influencing market sentiment.
See More
Trump Invites Top Executives for China Trip
- Executive Delegation: President-elect Trump has invited top executives, including Tesla's Elon Musk and Apple's Tim Cook, to join his trip to China, aiming to enhance U.S.-China business cooperation through high-level engagement.
- Broad Agenda: The summit is expected to cover a wide range of topics, including trade, artificial intelligence, export controls, Taiwan, and the Iran war, indicating a desire to ease tensions through dialogue after recent escalations.
- Business Deal Expectations: Trump hopes to secure a series of business deals and purchase agreements during the visit, which, if successful, could enhance U.S. companies' competitiveness in the Chinese market and foster bilateral economic relations.
- Diverse Executive List: The delegation includes executives from various sectors, such as Stephen Schwarzman of Blackstone and Jane Fraser of Citigroup, reflecting U.S. companies' commitment to the Chinese market and willingness to collaborate.
See More
Illumina Reports Q1 Results Exceeding Revenue Expectations
- Performance Exceeds Expectations: Illumina's Q1 revenue reached $1.09 billion, reflecting a 4.8% year-on-year growth that surpassed analyst expectations of $1.07 billion, indicating strong performance in the genomics sector and potential for stock price appreciation.
- Profitability Improvement: The adjusted EPS was $1.15, exceeding the $1.05 consensus estimate by 9%, while adjusted operating income stood at $239 million with a 21.9% margin, showcasing the company's success in cost control and operational efficiency.
- Strong Clinical Demand: Clinical sequencing now accounts for over 65% of the company's consumables revenue, with more than 80 NovaSeq X instruments placed in the quarter, driving revenue growth and indicating sustained demand for high-throughput sequencing.
- Innovation-Driven Growth: Illumina plans to launch new high-throughput flow cells and spatial transcriptomics solutions to enhance the capabilities of the NovaSeq X platform, expected to further expand market share and strengthen competitive positioning.
See More
Illumina Q1 2026 Earnings Call Highlights
- Performance Exceeds Expectations: Illumina reported Q1 revenue of $1.09 billion, exceeding the midpoint of guidance by $20 million, primarily driven by strong instrument and clinical consumable sales, indicating sustained growth potential in clinical markets.
- Guidance Raised for the Year: Management raised the 2026 revenue outlook to $4.52 billion to $4.62 billion and non-GAAP EPS expectations to $5.15 to $5.30, reflecting confidence in future performance and robust market demand.
- Product Innovation Progress: Illumina launched TruPath and is on track to introduce its spatial transcriptomics offering later this year, showcasing the company's ongoing commitment to technological innovation aimed at solidifying its market leadership.
- Expanded Buyback Program: The company repurchased 2 million shares for approximately $242 million in Q1 and announced an additional $1.5 billion share repurchase program, demonstrating management's confidence in future growth and commitment to shareholders.
See More
